Purepac Approvals Re-Start With Glucophage XR Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clearance of the company’s ANDA for metformin extended-release could bode well for Purepac’s chances that its generic version of Neurontin tablets will soon be approved. Approval of Purepac’s solid oral dose forms have been on hold due to manufacturing compliance issues.
You may also be interested in...
Gabapentin Injunction Hearing Delayed
A hearing on Pfizer's request for an injunction to prevent Purepac's launch of generic Neurontin has been postponed from Oct. 1 to the week of Oct. 4.
Purepac Free To Launch Neurontin Generic After Court Lifts Stay
The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.
Ranbaxy Glucophage XR Generic Uses Barr's 180-Day Exclusivity
Barr "selectively waived" its second-round of 180-day exclusivity to Ranbaxy. FDA had previously withdrawn tentative approval of Barr's ANDA due to concerns about the product's raw material supplier.